News

Xenazine is said to be the first and only FDA-approved treatment for any symptom of Huntington’s disease (HD) and is expected to be available later 2008. A double-blind,

Under the memorandum of understanding (MoU), AstraZeneca and the Singapore institutions will be entering into a collaborative agreement that spans both clinical and pre-clinical development activities. Under the

Additionally, Ed Spencer Jr, founder and chairman of Affinity Capital Management, will join the Spineology board of directors as the company evolves its commercialization and product development efforts

The company has appointed Eric Chan, Tongjitang’s financial controller, as the interim CFO and is beginning a search for a new CFO. Xiaochun Wang, CEO and chairman of

This clearance covers the Iridex IQ 532, IQ 577, IQ 630-670, and IQ 810 laser systems and their associated delivery devices to deliver laser energy in either CW-Pulse,

Fusilev, a novel folate analog, is available in 50mg vials of freeze-dried powder. It is the pharmacologically active isomer of leucovorin. Fusilev rescue is indicated after high-dose methotrexate

In this role, Dr Lasowski will lead business development activities for the company, assessing opportunities to potentially expand and diversify Onyx’s portfolio. Most recently, Dr Lasowski was the

The trial is a double blind, comparator controlled, randomized study comparing 400mg of Bronchitol twice a day to control. The trial includes a 26-week efficacy and safety component,

The Phase IIa trial was a randomized, double-blind, placebo-controlled, single ascending dose study in 21 volunteers with controlled hypertension who received the medication or placebo subcutaneously. The purpose